Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to -$22.2 million.

  • Maravai Lifesciences Holdings' Free Cash Flow fell 497.71% to -$18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.3 million, marking a year-over-year decrease of 519.01%. This contributed to the annual value of -$22.2 million for FY2024, which is 136.58% down from last year.
  • According to the latest figures from FY2024, Maravai Lifesciences Holdings' Free Cash Flow is -$22.2 million, which was down 136.58% from $60.7 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Free Cash Flow ranged from a high of $518.9 million in FY2022 and a low of -$22.2 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was $60.7 million (2023), whereas its average is $185.8 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Free Cash Flow spiked by 1,719.71% in 2020, and later crashed by 136.58% in 2024.
  • Maravai Lifesciences Holdings' Free Cash Flow (Yearly) stood at $126.8 million in 2020, then soared by 179.01% to $353.7 million in 2021, then skyrocketed by 46.69% to $518.9 million in 2022, then tumbled by 88.31% to $60.7 million in 2023, then slumped by 136.58% to -$22.2 million in 2024.